Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2022-10-03 00:00:00 ET · period of report 2022-10-03 · accession 0001725160-22-000178 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-10-03 | 2022-10-03 | ZNTL | Brownstein Carrie | Chief Medical Off | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
| DM | 2022-10-03 | 2022-10-03 | ZNTL | Brownstein Carrie | Chief Medical Off | A - Grant | $0.00 | +400.0K | 100.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-03 | A | A | 100,000 | $0.00 | 100,000 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted by the Issuer under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan") as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years: 25% of the RSUs will vest on each of the first, second, third and fourth anniversaries of the date of grant. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-10-03 | A | A | 300,000 | $0.00 | 300,000 | D | $22.21 · — to 2032-10-02 | 300,000 Common Stock | (F2) The options were granted by the Issuer under the 2022 Inducement Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-10-03 | A | A | 100,000 | $0.00 | 100,000 | D | $22.21 · — to 2032-10-02 | 100,000 Common Stock | (F3) The options were granted by the Issuer under the 2022 Inducement Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest as to 100% of the shares on the earlier of (a) FDA approval of a Zentalis product or (b) a Change in Control (as defined in the 2022 Inducement Plan). |